GlassScriptPhysician profile
Michael A Horseman
NPI 1245297993
$13,079.63
in general payments reported to CMS, 2019-2025
52 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,445 · 2020: $1,221 · 2021: $2,471 · 2022: $2,366 · 2023: $2,181 · 2024: $1,919 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,576.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,151.92 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,476.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,457.37 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Lilly USA, LLC | $1,185.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,098.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $995.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $769.92 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $631.02 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $397.60 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $264.68 | 2019-2022 | |
| Astellas Pharma US INC | $256.97 | 2020-2025 | Veozah |
| Amarin Pharma, INC. | $249.08 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $162.49 | 2019-2023 | Livalo, Seglentis |
| Biohaven Pharmaceuticals, INC. | $146.22 | 2020-2021 | |
| Exact Sciences Corporation | $126.49 | 2023-2025 | Cologuard Collection Kit |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Horseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.